{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:49:24Z","timestamp":1791442164742,"version":"4.3.3"},"reference-count":15,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"DOI":"10.1080\/14712598.2026.2744417","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:45:52Z","timestamp":1791377152000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A tale of two triplets: tafasitamab or epcoritamab in combination with rituximab and lenalidomide in relapsed\/refractory follicular lymphoma"],"prefix":"10.1080","author":[{"given":"Taylor S.","family":"White","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelynn","family":"Granger","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Galloway","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Karabinos","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Reinfried","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70070"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00262"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01770"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01778-7"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02360-8"},{"key":"e_1_3_3_12_1","volume-title":"Monjuvi (tafasitamab) [Prescribing information]","year":"2025","unstructured":"Monjuvi (tafasitamab) [Prescribing information]. Wilmington (DE): Incyte Corporation; 2025 Jun."},{"key":"e_1_3_3_13_1","volume-title":"Epkinly (epcoritamab) [prescribing information]","year":"2026","unstructured":"Epkinly (epcoritamab) [prescribing information]. Plainsboro (NJ): Genmab US Inc; 2026 Jun."},{"key":"e_1_3_3_14_1","first-page":"Abstract PS2035","article-title":"Anchored matching-adjusted indirect comparison of epcoritamab, lenalidomide, and rituximab vs tafasitamab, lenalidomide, and rituximab in relapsed\/refractory follicular lymphoma: EPCORE FL-1 vs inMIND","author":"Linton K","year":"2026","unstructured":"Linton K, Levy MY, Maruyama D, et al. Anchored matching-adjusted indirect comparison of epcoritamab, lenalidomide, and rituximab vs tafasitamab, lenalidomide, and rituximab in relapsed\/refractory follicular lymphoma: EPCORE FL-1 vs inMIND. Hemasphere. 2026;Supplement:Abstract PS2035.","journal-title":"Hemasphere"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5515"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024526"},{"key":"e_1_3_3_17_1","first-page":"Abstract PB4470","article-title":"Cost per complete responder for epcoritamab + lenalidomide and rituximab (R2) versus tafasitamab + R2 in relapsed or refractory follicular lymphoma: a US medicare perspective","author":"Wang T","year":"2026","unstructured":"Wang T, Wang T, Gao W, et al. Cost per complete responder for epcoritamab + lenalidomide and rituximab (R2) versus tafasitamab + R2 in relapsed or refractory follicular lymphoma: a US medicare perspective. Hemasphere. 2026;Supplement:Abstract PB4470.","journal-title":"Hemasphere"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2744417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2744417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2744417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:51:07Z","timestamp":1791438667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2744417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":15,"alternative-id":["10.1080\/14712598.2026.2744417"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2744417","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}